We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway.
- Authors
Lei Ma; Ke Huang; Haibo Zhang; Eungyung Kim; Hyeonjin Kim; Zhibin Liu; Chae Yeon Kim; Kanghyun Park; Raza, Muhammad Atif; Kirim Kim; Junkoo Yi; Yonghun Sung; Zae Young Ryoo; Yong-Gun Kim; Myoung Ok Kim
- Abstract
This article examines the potential of imatinib, an anti-cancer drug, in treating oral squamous cell carcinoma (OSCC). The study found that imatinib effectively inhibited the growth and migration of OSCC cells and induced cell death. These effects were achieved by targeting the PI3K/AKT/mTOR signaling pathway. The findings suggest that imatinib could be a promising treatment option for OSCC and potentially other types of cancer. The article provides valuable insights into the molecular mechanisms of imatinib and its potential as a therapeutic strategy.
- Subjects
IMATINIB; TREATMENT of oral cancer; MTOR protein; PI3K/AKT/MTOR pathway; CELL survival
- Publication
Journal of Cancer, 2024, Vol 15, Issue 3, p659
- ISSN
1837-9664
- Publication type
Article
- DOI
10.7150/jca.88555